A Phase 1, Multicenter, Open-label, Dose-escalation Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias
Latest Information Update: 17 Jan 2020
Price :
$35 *
At a glance
- Drugs SGI 1776 (Primary)
- Indications Leukaemia
- Focus Adverse reactions; First in man
- Sponsors Astex Pharmaceuticals
- 28 Nov 2011 Company added in the association field and additional lead trial center identified as reported by ClinicalTrials.gov.
- 18 Nov 2010 Status changed from active, no longer recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 18 Nov 2010 New trial record